Flagship’s Pioneering Medicines initiative could acquire Omega’s assets via a stalking horse bid, according to a regulatory ...

Sen. Bill Cassidy, whose “yes” vote advanced Kennedy’s nomination as health secretary, said Kennedy promised to maintain a ...

Louisiana Sen. Bill Cassidy joined his Republican colleagues in voting to advance Kennedy's nomination to a vote by the full ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

PSI is recognized as a remarkably stable CRO in an industry known for its unpredictability. Since the company’s establishment ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

A recent report from Stifel showed that 30% of licensing deals from big pharma companies now involve a Chinese biotech.